April 23crashracingpcHengdi Pharmaceutical released its annual performance report saying thatcrashracingpc, operating income in 2023 is approximately 6crashracingpc.63 billion yuan, a year-on-year increase of 28.crashracingpc76%; net profit attributable to shareholders of listed companies was approximately 176 million yuan, a year-on-year increase of 40%; basic earnings per share was 0.61 yuan, a year-on-year increase of 38.64%.
(Article source: Beijing News)